Transitional Cell Carcinoma Terminated Phase Trials for Erdafitinib (DB12147)

Also known as: Carcinoma, Transitional Cell / Carcinoma transitional cell / Transitional cell carcinoma (morphologic abnormality)

IndicationStatusPhase
DBCOND0031000 (Transitional Cell Carcinoma)TerminatedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05052372Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib